ABCL - AbCellera Biologics GAAP EPS of $0.54 revenue of $317M May, 10 2022 04:45 PM AbCellera Biologics Inc. AbCellera Biologics press release (NASDAQ:ABCL): Q1 GAAP EPS of $0.54. Revenue of $317M (+56.4% Y/Y). Shares +4.07%. For further details see: AbCellera Biologics GAAP EPS of $0.54, revenue of $317M